Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.74 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229702 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL3222537 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL8041092 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL8035165 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL1643773 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL10591581 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL2674837 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL8040666 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| Hydrochloric Acid SCHEMBL7091202 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 | |
| SCHEMBL3213446 | 0.98 | KCNA3 (0.73) | KCNA3TAAR1LTA4HPLA2G2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112795962-B | Leveling agent, electroplating solution and application thereof | 广东东硕科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-112795962-A | Leveling agent, electroplating solution and application thereof | 广东东硕科技有限公司 | 2021-05-14 | — | — | CN | claimed |
| CN-106450499-A | Lead-acid storage battery electrolyte and preparation method thereof | 陈申申 | 2017-02-22 | — | — | CN | claimed |
| CN-106384847-A | Storage battery electrolyte and preparation method and storage battery thereof | 叶晓东 | 2017-02-08 | — | — | CN | claimed |
| US-6489349-B1 | TREATING AN AUTOIMMUNE DISORDER WITH AN ALKYLAMINE SUBSTITUTED PYRIDINE | TARGACEPT, INC. | 2002-12-03 | — | — | US | claimed |
| EP-1171127-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | Targacept, Inc. (US) | 2002-01-16 | — | — | EP | claimed |
| US-6166048-A | Pharmaceutical compositions for inhibition of cytokine production and secretion | TARGACEPT, INC. (US) | 2000-12-26 | — | — | US | claimed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | claimed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-2526138-B1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN II LTD (GB) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024015277-A1 | CERAMIC ION EXCHANGE MATERIALS WITH HYDROPHOBIC GROUPS | Membrion, Inc. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11874278-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-4431585-A | THIAZOLE AND THIOPHENE DYES; DIAZOTIZATION; COUPLING | CASSELLA AKTIENGESELLSCHAFT (DE) | 1984-02-14 | — | — | US | disclosed |
| EP-0010256-B1 | PROCESS FOR PREPARING SYMMETRIC 1,3-DISUBSTITUTED UREAS | BASF Aktiengesellschaft (DE) | 1982-12-29 | — | — | EP | disclosed |
| US-4329283-A | DISPERSE DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-11 | — | — | US | disclosed |
| EP-0035671-A1 | Water-insoluble azo dyestuffs, methods for their preparation and their use in dyeing and printing synthetic hydrophobic fibre materials | CASSELLA Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | disclosed |
| EP-0010256-A2 | Process for preparing symmetric 1,3-disubstituted ureas | BASF Aktiengesellschaft (DE) | 1980-04-30 | — | — | EP | disclosed |
| US-3985835-A | A PHOSPHORUS-HALOGEN-NITROGEN CONTAINING COMPOUND | ALELIO GAETANO F D | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11874278-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | KCNA3 4667/4885TAAR1 2788/4885LTA4H 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.